Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Royal Bank of Canada lowered their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ MRNS opened at $0.54 on Wednesday. The stock has a market capitalization of $29.85 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $10.50. The stock has a 50 day moving average price of $0.40 and a 200 day moving average price of $0.95.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MRNS. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at about $28,000. AQR Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $64,000. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals during the third quarter worth approximately $104,000. Finally, JPMorgan Chase & Co. increased its stake in Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 126,752 shares during the period. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.